Cognia Begins Market Expansion with Appointment of Robert Merold as CEO, Dr. David Rubin CSO.NEW YORK -- Cognia Corporation, a pioneer in producing and aggregating biological information, today announced the start of a major commercial expansion with the appointment of Robert N. Merold as President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and David M. Rubin, Ph.D., as CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. and SVP SVP S'il Vous Plaît (French: Please) SVP Senior Vice President SVP Schweizerische Volkspartei (Swiss People~s Party) SVP Society of Vertebrate Paleontology SVP Social Venture Partners SVP St Vincent de Paul of Product Management. "Cognia has developed to the point where it is clear there is strong commercial potential", stated Cognia Chairman Paul Creager. "Bob has a unique mix of experience, knowledge and skills to make Cognia a $100M company within five years." Merold has served on the Cognia Board since 2002. He consults with numerous start-up companies and venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] on healthcare information and software businesses. Previously, he was COO and Board member of Proteome pro·te·ome n. The complete set of proteins that are produced by the genes of an organism. proteome the entire complement of proteins produced by a cell. , a venture-back curated database company sold to Incyte Genomics in 2001, and has held executive positions at IMS Health, Bristol-Myers Squibb and Procter & Gamble. "Cognia is simply a very exciting opportunity," said Merold. "I've had the pleasure of working closely with the team over the past year to plan the commercial expansion; what they have built will be transforming." "I'm also thrilled Dr. David Rubin will lead our product efforts as CSO", Merold added. Dr. Rubin, a Harvard trained proteomics expert was a company founder. Previously he held positions at IBM Global Services IBM Global Services is the world's largest business and technology services provider. It is the fastest growing part of IBM, with over 190,000 professionals serving customers in more than 160 countries. and The Wilkerson Group. "David did a spectacular job developing the company to this point. We've worked very closely together this past year and he can now focus his talents to drive our expanding product line." Cognia currently sells Cognia Molecular, a software system for aggregating disparate biological and chemical information used for drug research. Cognia also has a $6.5M contract with ITI (Information Technology Industry Council, Washington, DC, www.itic.org) Formerly the Computer and Business Equipment Manufacturers Association (CBEMA), founded in 1916. ITI is a membership organization composed of approximately 30 large high-tech companies. of Scotland for building a text-mining platform, leveraging world-class algorithms from the University of Edinburgh (body, education) University of Edinburgh - A university in the centre of Scotland's capital. The University of Edinburgh has been promoting and setting standards in education for over 400 years. with Cognia Molecular. "Over the next six months we will be making further announcements about product and market plans that will demonstrate why Cognia is so exciting, and help customers see how much value we will be creating for them," Merold promised. Cognia is headquartered in New York with an office in Edinburgh, Scotland. About Cognia Cognia develops and distributes information solutions for pharmaceutical and biotechnology companies designed to cost-effectively accelerate discovery and research processes by harnessing the power of disparate information. Cognia's information management platform, Cognia Molecular, provides a relational database structure that carefully considers the myriad complexities of biology as well as input tools for integrating proprietary, commercial and public information, and analysis tools for analysis and visualization. Cognia also provides Integrated Content Modules and Curation Services. For more information, please visit www.cognia.com or email Cognia at productinfo@cognia.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion